Truncated Delta-Plasminogen for Bacterial Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant plasminogen are hindered by its complex structure, leading to insoluble inclusion bodies in bacterial systems and cytotoxicity in mammalian cells, making large-scale production challenging, especially due to activation into plasmin and associated cytotoxicity.
Innovation Solution
A modified recombinant protein, delta-plasminogen, is developed with a single N-terminal kringle domain and a C-terminal serine protease domain, capable of binding immobilized lysine, which is designed for production in bacterial cells, offering improved solubility and reduced cytotoxicity by lacking certain negative characteristics of full-length plasminogen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If full-length plasminogen is produced in bacterial expression systems, then production is attempted, but the protein forms insoluble inclusion bodies and cannot be re-folded
Solution Approach 1:
The plasminogen molecule is divided into separate domains (kringle domains and serine protease domain). A truncated version retaining only kringle 1 and the serine protease domain is produced, which maintains essential functions while improving solubility and enabling bacterial expression without inclusion body formation.
Solution Approach 2:
The problematic middle kringle domains (K2-K5) are removed from the full-length plasminogen sequence. This extraction of the troublesome segments leaves a simplified structure that is soluble in bacterial systems while preserving the N-terminal kringle 1 domain responsible for fibrin binding and the C-terminal serine protease domain for catalytic activity.
2Productivity
If plasminogen is expressed in mammalian cells, then production is achieved, but intracellular activation into plasmin causes cytotoxicity
Solution Approach 1:
The truncated plasminogen structure removes sequences that are prone to premature activation. By retaining only the essential N-terminal kringle 1 domain and C-terminal serine protease domain, the molecule is less susceptible to intracellular activation while maintaining thrombolytic function, thereby reducing cytotoxicity in mammalian expression systems.
3Reliability
If insect cells are used for plasminogen production, then fully active plasminogen is produced, but the system is not suitable for large-scale production due to low yield
Solution Approach 1:
The invention changes the structural parameters of plasminogen by creating a truncated version with reduced molecular weight and simplified domain structure. This modified structure expresses efficiently in bacterial systems with high yield while maintaining sufficient catalytic activity for thrombolytic applications, overcoming the low productivity limitation of insect cell systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Delta-plasminogen is produced in substantial quantities with increased specific activity, facilitated by its lower molecular weight and lack of glycosylation sites, allowing for efficient thrombolytic efficacy and rapid inhibition by α2-antiplasmin, reducing bleeding complications.
Implementation Method 1
the polypeptide binds to immobilized lysine. The N-terminal kringle domain can be homologous to kringle 1 or kringle 4 of native human plasminogen
Data Source
AI summary
Methods of using polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided, including methods related to vitrectomy or vitreolysis. The plasmin(ogen) molecule has a single kringel domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.